However, studies are ongoing to expand the potential therapeutic benefits of CGRP antagonism in patients with chronic visceral pain, trigeminal neuralgia, fibromyalgia, peripheral neuropathy, and opioid tolerance. The gene discussed is CALCA; the disease is trigeminal neuralgia.